Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Дата публикации: 26-06-2026 01:06:06

NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of children six years of age and older with...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2	0	19.68	29-06-2026
2	New PILL for psoriasis approved... giving hope to millions suffering from debilitating skin condition	0	5.26	18-03-2026
3	FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma	0	12.93	10-07-2026
4	Glenmark Receives U.S. FDA Approval to Expand the Use of Ryaltris Nasal Spray for Children Aged 6 to Less Than 12 Years	0	13.57	21-07-2026
5	Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod	0	18.01	30-07-2026
6	FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva	0	15.91	19-08-2026
7	Xeomin Approved For Expanded Indication in Pediatric Upper Limb Spasticity Patients with Cerebral Palsy Following FDA Label Update	0	10.02	26-06-2026
8	Gene therapy for children with sickle cell disease approved by FDA	5	7	08-07-2026
9	FDA approves gene therapy for children with sickle cell disease ages 2+	5	7	09-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 13.95. Источник: www.drugs.com.